Evidence map›Paper›PMID 35950859›Full record

ArticleJournal of virology2022

Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.

Sizhu Duan, Xin Yu, Chu Wang, Lina Meng, Yanxin Gai, Yan Zhou, Tiejun Gu, Bin Yu, Jiaxin Wu, Xianghui Yu

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sizhu DuanNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Xin YuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Chu WangNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Lina MengNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Yanxin GaiNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Yan ZhouNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Tiejun GuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Bin YuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Jiaxin WuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.
Xianghui YuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin Universitygrid.64924.3d, Changchun, Jilin Province, China.ORCID 0000-0001-7739-1386
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein B mRNA-editing catalytic polypeptide-like 3 family members (APOBEC3s) are host restriction factors that inhibit viral replication. Viral infectivity factor (Vif), a human immunodeficiency virus type 1 (HIV-1) accessory protein, mediates the degradation of APOBEC3s by forming the Vif-E3 complex, in which core-binding factor beta (CBFβ) is an essential molecular chaperone. Here, we screened nonfunctional Vif mutants with high affinity for CBFβ to inhibit HIV-1 in a dominant negative manner. We applied the yeast surface display technology to express Vif random mutant libraries, and mutants showing high CBFβ affinity were screened using flow cytometry. Most of the screened Vif mutants containing random mutations of different frequencies were able to rescue APOBEC3G (A3G). In the subsequent screening, three of the mutants restricted HIV-1, recovered G-to-A hypermutation, and rescued APOBEC3s. Among them, Vif-6M showed a cross-protection effect toward APOBEC3C, APOBEC3F, and African green monkey A3G. Stable expression of Vif-6M in T lymphocytes inhibited the viral replication in newly HIV-1-infected cells and the chronically infected cell line H9/HXB2. Furthermore, the expression of Vif-6M provided a survival advantage to T lymphocytes infected with HIV-1. These results suggest that dominant negative Vif mutants acting on the Vif-CBFβ target potently restrict HIV-1.

Indexed as

Core Binding Factor beta SubunitHIV-1HIV Infectionsvif Gene Products, Human Immunodeficiency VirusAnimalsAPOBEC DeaminasesCell LineChlorocebus aethiopsHost-Pathogen InteractionsHumansT-LymphocytesVirus ReplicationAPOBEC DeaminasesCore Binding Factor beta Subunitvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1apolipoprotein B mRNA-editing catalytic polypeptide-like 3 family member (APOBEC3)core-binding factor beta (CBFβ)dominant negative mutanthuman immunodeficiency virus (HIV)viral infectivity factor (Vif)

Identifiers

PMID35950859
PMCPMC9472641
OpenAlexW4290804174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.